NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
Clinical Trials
21 trialsNCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT00679289 2022-10-12
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT00398450 2021-03-03
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
University of California, San Diego
Phase 1 Completed
NCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00629200 2018-11-15
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03435302 2018-02-19
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 3 Unknown
NCT00311558 2018-01-26
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
The Cleveland Clinic
Phase 1 Terminated
NCT01622933 2017-08-31
Multiple Antigen-Engineered DC Vaccine for Melanoma
University of Pittsburgh
Phase 1 Completed
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02074605 2014-02-28
Cognitive Effects of Interferon in Patients With Melanoma
University of Arizona
Completed
NCT01743157 2013-08-29
BBI
California Pacific Medical Center Research Institute
Phase 1/2 Completed
NCT01782508 2013-02-04
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00221702 2010-10-13
EADO
University Hospital, Bordeaux
Phase 3 Completed
NCT00963664 2009-09-09
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
Phase 2 Withdrawn
NCT00226408 2006-06-21
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
Dermatologic Cooperative Oncology Group
Phase 3 Unknown